Debra BorchardtNovember 15, 2023
Even if Enveric receives regulatory approval for its compounds, it would still need funds for manufacturing.
Category: Psychedelics
Debra BorchardtNovember 15, 2023Debra BorchardtNovember 15, 2023
Atai says it is has enough funds to last until the first half of 2026
Debra BorchardtNovember 15, 2023
The company attributed its lack of revenue to a change in payment processors.
John SchroyerNovember 8, 2023
Pain and depression top the list of conditions being treated with the psychedelic drug.
John SchroyerNovember 2, 2023
The company said it has enough cash to continue operations into 2026.
Adam JacksonNovember 2, 2023
The firm says its existing cash will fund it through 2025.
John SchroyerNovember 1, 2023
To facilitate the acquisition, Beckley founded a new subsidiary, NueCo Holdings PBC.
John SchroyerOctober 31, 2023
Comments on the proposals can be submitted to DEA until Nov. 30.
Debra BorchardtOctober 27, 2023
This week three doctors reviewed the test results comparing the two options for treatment-resistant depression (TRD). Electroconvulsive therapy (ECT) is considered the gold standard for TRD but is not widely used in the U.S. Ketamine infusion has gained more attention in the U.S. as a treatment for TRD as a rapid-acting option, but also one […]
Debra BorchardtOctober 26, 2023
Mary-Rose Hughes will fill the role on an interim basis.
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.